Discovery of ZSL-M028: A Potent, Selective and Orally Available Quinazoline-Based PLK4 Inhibitor Targeting TRIM37 -Amplified Neuroblastoma
Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 19065-19087
DOI: 10.1021/acs.jmedchem.6c01348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.07.2026. Verfasst von Nian Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical Uni…. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Quinazolines, Neuroblastoma, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: 3D BioOptima (Suzhou), Program for Innovative Research Team of the Ministry of Education, Program for Liaoning Innovative Research Team in University.
Abstract (Originalsprache)
Polo-like kinase 4 (PLK4), a master regulator of centrosome duplication, has emerged as an attractive therapeutic target in oncology. Notably, the synthetic lethality between PLK4 inhibition and TRIM37 amplification provides a strong rationale for targeted tumor intervention. However, the limited structural diversity of current PLK4 inhibitors constrains further development. Herein, structure-guided scaffold-hopping and fragment growth strategies were employed to develop a series of structurally novel quinazoline-based PLK4 inhibitors. The optimized compound B33 (ZSL-M028) exhibited potent PLK4 inhibition (IC50 = 1.1 nM), excellent selectivity over Aurora A kinase (over 1600-fold), and favorable ADME and pharmacokinetic properties, including an oral bioavailability of 55.4%. M028 further demonstrated significant in vitro and in vivo antitumor activity against TRIM37-amplified neuroblastoma with a favorable safety profile. Overall, M028 represents a promising lead for PLK4 inhibition, and offers new opportunities for precision therapy in TRIM37-amplified neuroblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang110016, PR China.
- 3D BioOptima, 1338 Wuzhong Avenue, Suzhou215104, China.
- Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California94305, United States.
ORCID-Profile: Dongmei Zhao
Förderung
- 3D BioOptima (Suzhou)
- Program for Innovative Research Team of the Ministry of Education
- Program for Liaoning Innovative Research Team in University
Zitieren
APA
Liu, N., Qi, Z., Sun, W., Tong, M., Shi, X., Wang, H., Mu, S., Hu, N., Luo, Z., Fan, C., Zhang, H., Gao, Z., Sun, Y., Zhao, D., & Cheng, M. (2026). Discovery of ZSL-M028: A Potent, Selective and Orally Available Quinazoline-Based PLK4 Inhibitor Targeting TRIM37 -Amplified Neuroblastoma. Journal of Medicinal Chemistry, 69(15), 19065-19087. https://doi.org/10.1021/acs.jmedchem.6c01348
Vancouver
Liu N, Qi Z, Sun W, Tong M, Shi X, Wang H, et al. Discovery of ZSL-M028: A Potent, Selective and Orally Available Quinazoline-Based PLK4 Inhibitor Targeting TRIM37 -Amplified Neuroblastoma. Journal of Medicinal Chemistry. 2026;69(15):19065-19087. doi:10.1021/acs.jmedchem.6c01348
BibTeX
@article{Liu2026,
author = {Liu, Nian and Qi, Zehui and Sun, Wenqiang and Tong, Minghui and Shi, Xuan and Wang, Han and Mu, Shuyi and Hu, Ningyuan and Luo, Zirui and Fan, Cunzheng and Zhang, Haoyu and Gao, Zixuan and Sun, Yin and Zhao, Dongmei and Cheng, Maosheng},
title = {Discovery of ZSL-M028: A Potent, Selective and Orally Available Quinazoline-Based PLK4 Inhibitor Targeting TRIM37 -Amplified Neuroblastoma},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {15},
pages = {19065--19087},
doi = {10.1021/acs.jmedchem.6c01348}
}
EUVIMED